1. Background
2. Objectives
3. Patients and Methods
3.1. Participants
3.2. Laboratory Tests
3.3. Ethical Considerations
3.4. Statistical Analysis
4. Results
| Control (n = 130) | Atopic Dermatitis | P Valueb | ||||
|---|---|---|---|---|---|---|
| EH+, n = 50 | EH, n = 200 | Total, n = 250 | P Valuec | |||
| Male | 47 (36.2) | 30 (60.0) | 38 (19.0) | 68 (27.2) | < 0.001 | 0.07 |
| Mean age, y | 4.7 ± 4.4 | 4.2 ± 4.3 | 5.6 ± 4.7 | 5.3 ± 4.7 | 0.06 | 0.22 |
| 25-hydroxyvitamin D3, ng/mL, mean ± SD | 28.1 ± 11.5 | 25.2 ± 11.8 | 22.9 ± 10.4 | 25.0 ± 11.2 | 0.17 | < 0.001 |
| Vitamin D status | 0.04 | < 0.001 | ||||
| Sufficient, ≥ 30 | 62 (47.7) | 20 (40.0) | 45 (22.5) | 65 (26.0) | ||
| Insufficient, 20 - 29.9 | 33 (25.4) | 14 (28.0) | 69 (34.5) | 83 (33.2) | ||
| Deficient, < 20) | 35 (26.9) | 16 (32.0) | 86 (43.0) | 102 (40.8) | ||
| Sampling seasond | < 0.001 | < 0.001 | ||||
| Spring | 17 (13.1) | 12 (24.0) | 61 (30.5) | 73 (29.2) | ||
| Summer | 42 (32.3) | 25 (50.0) | 49 (24.5) | 74 (29.6) | ||
| Autumn | 36 (27.7) | 8 (16.0) | 47 (23.5) | 55 (22.0) | ||
| Winter | 35 (26.9) | 5 (10.0) | 43 (21.5) | 48 (19.2) | ||
Abbreviation: EH, eczema herpeticum.
aValues are presented as No. (%) or mean ±SD.
bControl group compared with atopic dermatitis group
cEH+ compared with EH-.
dSpring, March - May; Summer, June - August; Autumn, September - November; Winter, December - February.
| Variables | EH+ (n = 50) | EH- (n = 200) | P Value |
|---|---|---|---|
| Vaginal delivery | 32 (64.0) | 30 (60.0) | 0.43 |
| Parental allergy | 25 (50.0) | 131 (65.5) | 0.02 |
| Allergic rhinitis | 22 (44.0) | 95 (47.5) | |
| Contact dermatitis | 4 (8.0) | 66 (33.0) | |
| AD | 3 (6.0) | 5 (2.5) | |
| Bronchial asthma | 0 (0.0) | 3 (1.5) | |
| Age of AD onset, y | 1.7 ± 2.4 | 2.4 ± 2.9 | 0.09 |
| AD duration, y | 0.59 | ||
| < 1 | 20 (40.0) | 71 (35.5) | |
| 1 - 2 | 13 (26.0) | 45 (22.5) | |
| > 2 | 17 (34.0) | 84 (42.0) | |
| SCORAD index | 47.6 ± 17.7 | 33.6 ± 18.7 | < 0.001 |
| Severity | < 0.001 | ||
| Mild | 0 (0.0) | 37 (18.5) | |
| Moderate | 16 (32.0) | 103 (51.5) | |
| Severe | 34 (68.0) | 60 (30.0) | |
| Clinical symptoms | 37 (74.0) | ||
| Fever | 12 (24.0) | ||
| Systemic symptoms | 13 (26.0) | ||
| Keratoconjunctivitis | 12 (24.0) | ||
| Acyclovir treatment | 50 (100) | ||
| Intravenous | 21 (42.0) | ||
| Perioral | 29 (58.0) | ||
| Readmission | 4 (8.0) |
Abbreviations: AD, atopic dermatitis; EH, eczema herpeticum; SCORAD, SCORing atopic dermatitis.
aValues are presented as No. (%) or mean ±SD.
| Variables | EH+ (n = 50) | EH- (n=200) | P Value |
|---|---|---|---|
| Total protein, g/dL | 6.8 ± 0.5 | 7.0 ± 0.5 | < 0.001 |
| Albumin, g/dL | 4.3 ± 0.3 | 4.5 ± 0.3 | < 0.001 |
| IgA, IU/mL | 82.6 ± 69.2 | 96.2 ± 61.6 | 0.18 |
| IgG, IU/mL | 787.9 ± 237.7 | 846.9 ± 252.0 | 0.14 |
| IgM, IU/mL | 100.7 ± 43.7 | 113.5 ± 44.5 | 0.07 |
| Total IgE, IU/mL | 612.1 ± 986.0 | 521.4 ± 875.3 | 0.52 |
| ECP, µg/L | 16.5 ± 18.7 | 14.9 ± 17.6 | 0.58 |
| Total eosinophil count, /µL | 488.6 ± 435.7 | 494.2 ± 465.7 | 0.94 |
| Positive skin culture | < 0.001 | ||
| Staphylococcus aureus | 34 (68.0) | 87 (43.5) | |
| MRSA | 15 (30.0) | 23 (11.5) | |
| MSSA | 19 (38.0) | 64 (32.0) | |
| Coagulase Negative Staphylococcus | 11 (22.0) | 95 (47.5) |
Abbreviations: EH, eczema herpeticum, Total IgE, immunoglobulin E; ECP, eosinophil cationic protein; MRSA, methicillin-resistant Staphylococcus aureus, MSSA, methicillin-sensitive Staphylococcus aureus.
aValues are presented as No. (%) or mean ±SD.
| Factor | OR (95% CI) | P Value |
|---|---|---|
| Mean age, y | 1.13 (0.98-1.30) | 0.08 |
| Male gender | 2.56 (1.19-5.53) | 0.01 |
| 25-Hydroxyvitamin D3, ng/mL | 0.90 (0.96-1.03) | 0.90 |
| Total IgE, IU/mL | 1.00 (0.99-1.00)c | 0.41c |
| ECP, µg/L | 1.00 (0.98-1.02)c | 0.80c |
| Total eosinophil count, /µL | 1.00 (1.00-1.01)c | 0.34c |
| Positive skin culture | < 0.001c | |
| MRSA | 0.19 (0.04-0.92)c | 0.03c |
| MSSA | 0.42 (0.09-1.89)c | 0.26c |
| CNS | 1.54 (0.35-6.76) c | 0.56c |
Abbreviations: CNS, coagulase-negative Staphylococcus; ECP, eosinophil cationic protein; IgE, immunoglobulin E; MRSA, methicillin-resistant Staphylococcus aureus, MSSA, methicillin-sensitive Staphylococcus aureus.
aValues are presented as No. (%) or mean ±SD.